Articles On Noxopharm (ASX:NOX)

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Noxopharm CEO Dr Gisela Mautner added, “We are very grateful to the Tour de Cure team for funding this promising research. With this grant, our preclinical drug candidate is recognised as having potential that warrants further inves...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

  Local markets started slow before ripping into an all-time intraday high  10 of 11 sectors higher, benchmark closes 0.50pc up Small Caps led by Motio, Cue Energy and Sierra Rutile   Some strong earnings on the last day of February and...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  Local markets end +0.13% higher in quasi-comeback Consumer Staples soar on bumper Coles news, but offset by everyone else Small Caps led by Audeara on the back of a massive manufacturing sale   The indignation of Coles has led Consumer...

The ASX benchmark has closed slightly higher on Monday Energy Sector gains after oil prices rose over the weekend Small caps led Killi Resources, Nyrada and Viridis Mining   The Aussie sharemarket has ended the opening salvo of the week...

ASX set to fall despite a modest rally on Wall Street Microchip stocks fell as Microsoft unveiled its new custom AI chip Janus Henderson says investing in dividend stocks won’t always be a sure thing   Aussie shares are poised to open low...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

ASX200 closes 0.9pc higher Property stocks and IT sector enjoy huge day Small caps led by DCL   The Australian sharemarket has lifted strongly on Day Two of Trading in November, the Best Month for Trading Ever. Local investors got stuck r...

The S&P ASX 200 fell -3.8% in October with mid-caps falling -6.94% and small-caps down -5.45% for the month S&P ASX 200 Energy was the only sector that closed October in the black with all Australian equity factors in red Dimerix...

mRNA is set to be the new frontier in vaccines, but has serious side effects including inflammation ASX listed Noxopharm has a program to tackle this problem Stockhead reached out to Stockhead’s CEO, Gisela Mautner   Scientists have been...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

The Australian sharemarket increased in value on Wednesday, as China's gross domestic product (GDP) for July-September grew by 4.9% compared to the previous year.  At the closing bell, the S&P/ASX 200 was 0.3 per cent higher at 7,077.60...

  Don't miss Friday's webinar discussing imaging tech, laser tech and agricultural REITs. Click here to register. Whitehaven Coal (ASX:WHC) has been placed in a trading halt following an announcement by BHP that Whitehaven Coal is the prefe...

18 Oct 2023 - A snapshot of the stocks on the move, featuring Whitehaven Coal (ASX:WHC), Paradigm Biopharmaceuticals (ASX:PAR), Noxopharm (ASX:NOX) and Liontown Resources (ASX:LTR)…

Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni...

Benchmark ASX index finishes +1% higher ASX Sectors led by Utilities (+4.2%) and all ended higher on the day Funny bunch of small cap winners including MOB, CZR, NGL   The ASX200 doesn’t seem to mind a bit of war on Tuesday, rising very...

This week’s Bulls N’ Bears top ASX runner is… Noxopharm. It skyrocketed 323 per cent to join other impressive runners including Dimerix, Roots Sustainable Agricultural Technologies and Toys“R”Us.

Benchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Dimerix   The ASX200 is up +0.4% at  the end of Friday trade, making the week a 1% loss, which we’ll take at this stage. US equities ticked l...

Benchmark index finds some rare greenage, up 0.5% Property and IT Sectors lead broad-based gains, XEC Emerging Co’s index now down 14% from July highs Fascinating small caps action: led by Dimerix, Bluglass and Experience Co.   The ASX2...

The ASX200 is now at its lowest level in eleven months, closing down .8 of a per cent this afternoon. Across the sectors, it was a sea of red – with only utilities bucking the trend – up nearly .4 of a per cent. Financials dropped 1.5...

It's been another depressing session for the S&P/ASX 200 Index (ASX: XJO) this Wednesday, making it three for three so far this week. After tanking a horrid 1.3% yesterday, the ASX...

Benchmark index falls to 11-month lows Utilities only sector in green Small caps led by Noxopharm   Local markets have extended unexpected October losses on Wednesday as tech stocks, and the Financial Sector led losses on another bond-...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Fear continued to grip Wall Street last night, sending all of the United States' major indices backwards. The Dow Jones Industrial Average — an index tracking 30 of the most prominent listed companies in the US — fell 1.29% to 33,003.38 po...

It has been yet another difficult day for the S&P/ASX 200 Index (ASX: XJO). In afternoon trade, the benchmark index is down 1% to 6,871.1 points. Four ASX shares that are not letting that hold them back are listed below. Here's why the...

Australian biotechnology company Noxopharm (ASX: NOX) has been granted orphan drug designation (ODD) status by the US Food and Drug Administration for its CRO-67 preclinical drug candidate to treat pancreatic cancer. The FDA grants the stat...

04 Oct 2023 - A snapshot of the stocks on the move, featuring Noxopharm (ASX:NOX), Redstone Resources (ASX:RDS) and Lake Resources (ASX:LKE).

  Noxopharm (ASX:NOX) announces that the US FDA has granted Orphan Drug Designation (ODD) status to Noxopharm’s CRO-67 preclinical drug candidate, for the treatment of pancreatic cancer. Noxopharm CEO Dr Gisela Mautner said, “our pancreatic...

New Zealand's central bank is likely to maintain its current interest rates ahead of a general election, with all surveyed economists expecting no change at 5.5 percent. However, policymakers may emphasize the potential for future rate hike...

ASX to open lower, as markets fall in New York  US 10-year yields continue to threaten 5%, so everyone’s still upset  Noxopharm comes good on FDA AND… So. Much. Lithium. News.   Aussie shares are headed for another early October retreat...

The US FDA has granted Orphan Drug Designation status to Noxopharm's (ASX:NOX) CRO-67 preclinical drug candidate for the treatment of pancreatic cancer.

It has been a stunning start to the day for ASX healthcare stock Noxopharm Ltd (ASX: NOX). In morning trade, the biotech company's shares are up 166% to 16.5 cents. Why is this ASX healthcare stock rocketing? Investors have been scrambling...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

ASX200 drops sharply on Wall Street worry Healthcare only sector to rise Small caps led by Noxopharm, Nimy Resources, Alderan and ECS Botanics   The ASX200 has inched below where it was at the start of 2023, while the Australian dollar...

Anatara to progress in Phase 1/2 clinical trial of bowel syndrome Noxopharm to present data at conference for pancreatic cancer   Anatara Lifesciences (ASX:ANR) surged 11% this morning after announcing positive results from Stage 1 of its...

Futures are tipping the ASX to open down this morning, following a mixed session of Wall Street and the impact of oil reaching an 11-month high. Some important news today to keep an eye out for include new retail trade data, job vacancie...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

The ASX 200 has had its worst day in roughly a month with a 1.29 percentage dip  The sectors were a shade of spilt claret, with Utilities and Real Estate leading losses Standout small caps: BCAL Diagnostics and American West Metals   Loca...

ASX dips 0.56% despite a solid kickstart first thing this morning InfoTech outperforms the market again, leading on +0.21% for the day Heavy Minerals banks a 90% bump on some big time garnet news   For 10 fantastic minutes this morning, l...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...